Information about The Medical Letter CME program is available at: medicalletter.org/cme-program.
The mission of The Medical Letter’s Continuing Medical Education (CME) Program is to support the professional development of healthcare providers including physicians, nurse practitioners, pharmacists, and physician associates by providing independent, unbiased drug information and treatment recommendations that are free of industry influence. The content of the educational activities primarily includes comparative reviews of pharmacologic treatment for common conditions and unbiased reviews of newly FDA-approved drugs that focus on their pharmacology, efficacy in clinical trials, dosage and administration, adverse effects, and drug interactions. The Medical Letter delivers educational content in the form of self-study material.
The expected outcome of the CME program is to increase the participant’s knowledge about, or apply knowledge into practice after assimilating, information presented in materials contained in The Medical Letter.
The Medical Letter will strive to continually improve the CME program through periodic assessment of the program and activities. The Medical Letter aims to be a leader in supporting the professional development of healthcare providers by providing continuing medical education that is unbiased and free of pharmaceutical industry influence.
The Medical Letter does not sell advertising or receive any commercial support.
Through this program, The Medical Letter expects to provide the health care community with unbiased, reliable, and timely educational content that they will use to make independent and informed therapeutic choices in their practice.
Activity participants will read and assimilate unbiased reviews of FDA-approved and off-label uses of drugs and other treatment modalities.
Activity participants will be able to select and prescribe, or confirm the appropriateness of the prescribed usage of, the drugs and other therapeutic modalities discussed in The Medical Letter with specific attention to clinical trials, pathophysiology, dosage and administration, drug metabolism and interactions, and patient management.
Activity participants will make independent and informed therapeutic choices in their practice.
Participants in the program have indicated their interest in this subject matter and need for information by subscribing to The Medical Letter, the content of which provides the basis for this activity. The activity is periodically evaluated, and comments and suggestions from subscribers reviewed and implemented as deemed appropriate.
CONFLICT OF INTEREST
The Medical Letter, Inc. is an independent nonprofit organization that provides healthcare professionals with unbiased drug information. The Medical Letter, Inc. is supported by subscription fees and accepts no advertising. The editorial process used for its publications relies on a review of published and unpublished literature, with an emphasis on controlled clinical trials and peer review. The questions in The Medical Letter CME Activities are designed and created by the editorial staff at The Medical Letter. All individuals involved in the content on which this activity is based are required to disclose any relevant financial relationship(s) they have with a commercial interest that benefits the individual in any financial amount that has occurred within the past 24 months. Any faculty whose disclosed relationships prove to create an irresolvable conflict of interest, with regard to their contribution to the activity, will not be permitted to participate.
The Medical Letter requires that individuals responsible for the content on which a CME activity is based disclose to the audience when a conflict exists and when discussing any unlabeled or investigational use of any commercial product, or device, not yet approved for use in the United States.
The content of The Medical Letter and related CME Program is controlled by the President, who declares no conflict of interest.
The Medical Letter is accredited by the Accreditation Council for Continuing Medical Education (ACCME) to provide continuing medical education for physicians. The Medical Letter Inc. designates this enduring material for a maximum of 2 AMA PRA Category 1 Credits(s)™.
Physicians should claim only the credit commensurate with the extent of their participation in the activity.
The AAFP has reviewed The Medical Letter Continuing Education Program, and deemed it acceptable for AAFP credit. Term of approval is from 01/01/2023 to 12/31/2023. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
This activity has been reviewed by the AAPA Review Panel and is compliant with AAPA CME Criteria. PAs should only claim credit commensurate with the extent of their participation.
Successful completion of the post-test is required to earn AAPA Category 1 CME credit. Successful completion is defined as a cumulative score of at least 70 percent correct.
The Medical Letter is accredited by the Accreditation Council for Pharmacy Education as a provider of continuing pharmacy education. This exam is acceptable for a maximum of 2.0 hours of knowledge-based continuing education credit (0.2 CEU).
The American Nurses Credentialing Center (ANCC) and the American Academy of Nurse Practitioners (AANP) accept AMA PRA Category 1 Credit™ from organizations accredited by the ACCME.
This activity, being ACCME (AMA) approved, is acceptable for Category 2-B credit by the American Osteopathic Association (AOA).
Physicians in Canada: Members of The College of Family Physicians of Canada are eligible to receive Mainpro-M1 credits (equivalent to AAFP Prescribed credits) as per our reciprocal agreement with the American Academy of Family Physicians.
A score of 70% or greater is required to pass the exam. For ACPE credit, CPE Monitor (NABP.net) is the only official source of credit/transcripts. Certificates/statements of credit will be emailed to those who submit and pass the exam.
PRINCIPAL FACULTY FOR CME ACTIVITY
Mark Abramowicz, M.D., President has disclosed no relevant financial relationships.
Jean-Marie Pflomm, Pharm.D., Editor in Chief has disclosed no relevant financial relationships.
Brinda M. Shah, Pharm.D., Consulting Editor has disclosed no relevant financial relationships.
PRIVACY AND CONFIDENTIALITY
The Medical Letter guarantees our firm commitment to your privacy. We do not sell any of your information. Secure server software (SSL) is used for commerce transactions through VeriSign, Inc. No credit card information is stored.
Windows 7/8/10/11, Mac OS X+; current versions of Microsoft IE/Edge, Mozilla Firefox, Google Chrome, Safari or any other compatible Web browser. High-speed connection.
For questions about this examination please call Customer Service at The Medical Letter at (800) 211-2769.